

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			C mplete if Known Application Number 09/724,940 Filing Date November 28, 2000 First Named Inventor Schenk, Dale B. Group Art Unit 4774 ICH Examiner Name Unassigned NICHOLS Attorney Docket Number 16270J-004751US		
Sheet	1	of	15		

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
ESN	200	09/441,140		Selman et al.	11-10-1999	
	202	00/480,007		Chen	N/A	
	205	00/404,001		Holtzman et al.	N/A	
	209	00/400,205		Rasmussen et al.	N/A	
	200	00/404,405		Holtzman et al.	N/A	
	207	00/404,400		Holtzman et al.	N/A	
	300	2001/0018053	A1	McMichael	08-30-2001	
	267	6,294,171	B2	McMichael	09-25-2001	
	234	6,284,221	B1	Schenk, et al.	09-04-2001	
	230	6,202,335	B1	Hsiao et al.	07-17-2001	
	231	6,114,133		Seubart et al.	09-05-2000	
	198	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,387		Stamler et al.	05-02-2000	
	221	5,989,588		Cobb et al.	11-23-1999	
	2	5,958,883		Snow	09-28-1999	
	3	5,955,317		Suzuki et al.	09-21-1999	
	4	5,955,079		Mond et al.	09-21-1999	
	5	5,977,399		Hsiao et al.	03-02-1999	
6	5,969,093		Weiner et al.	02-09-1999		
7	5,869,054		Weiner et al.	02-09-1999		
8	5,854,204		Findels et al.	12-29-1998		
9	5,851,998		Kline	12-22-1998		
10	5,849,298		Weiner et al.	12-15-1998		
11	5,837,473		Maggio et al.	11-17-1998		
12	5,788,180		Konig et al.	07-28-1998		
207	5,780,587		Potter	07-14-1998		
13	5,753,624		McMichael et al.	06-19-1998		
14	5,750,349		Suzuki et al.	05-12-1998		
197	5,744,388		Goldgaber et al.	04-28-1998		
211	5,736,142		Sette et al.	04-07-1998		
15	5,733,547		Weiner et al.	03-31-1998		
16	5,688,651		Solomon	11-18-1997		
17	5,679,348		Nesburn et al.	10-21-1997		
18	5,645,820		Hafler et al.	07-08-1997		

11-21-00
 400/2900

RECEIVED
 11-21-00

Examiner Signature		Date Considered	10/31/03
-----------------------	--	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1
PA 3147648 v22

TECH CENTER 1600/2900

02 AUG 27 PM 2:10

CONSIDERED; DO NOT PRINT.

RECEIVED
TO 100

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 15

Complete if Known

Application Number 09/724,940
Filing Date November 28, 2000
First Named Inventor Schenk, Dale B.
Group Art Unit 4771 KA
Examiner Name Unassigned DICKENS
Attorney Docket Number 15270J-004751US

19	5,641,474	—	Hafler et al.	06-24-1997	
20	5,641,473	—	Hafler et al.	06-24-1997	
21	5,612,486	—	McConlogue et al.	03-18-1997	
22	5,605,811	—	Seubert et al.	02-25-1997	
23	5,585,100	—	Mond et al.	12-17-1996	
24	5,571,500	—	Hafler et al.	11-05-1996	
25	5,571,499	—	Hafler et al.	11-05-1996	
175	5,441,870	—	Seubert, et al.	08-15-1995	
26	5,434,170	—	Andrulis, Jr.	07-18-1995	
27	5,387,742	—	Cordell	02-07-1995	
181	5,270,165	—	Van Nostrand et al.	12-14-1993	
284	5,231,170	—	Averback	1993-07-27	
28	5,231,000	—	Majocha et al.	07-27-1993	
29	5,220,013	—	Ponte et al.	06-15-1993	
30	5,208,036	—	Eppstein et al.	05-04-1993	
31	5,192,753	—	McGeer et al.	03-08-1993	
32	5,187,153	—	Cordell et al.	02-18-1993	
33	5,057,540	—	Kensil et al.	10-15-1991	
198	5,004,897	—	Pardridge	04-0201991	
34	4,866,829	—	Glenner et al.	05-19-1987	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ²	Number ¹	Kind Code ⁶ (if known)				
320	35	EP	911 036	A2		04-28-1999		
	36	EP	888 918	A2		10-07-1998		
	37	EP	863 211	A1		09-09-1998		
	38	EP	845 270	A1		06-03-1998		
	39	EP	782 859	A1		07-09-1997		
	40	EP	683 234	A1		11-22-1995		
	41	EP	666 080	A1		08-09-1995		
	42	EP	652 962	B1		12-16-1998		
	43	EP	639 081	B1		11-03-1999		
	44	EP	613 007	A2		08-31-1994		
	45	EP	594 607	B1		06-27-1997		
	46	EP	561 087	B1		08-04-1999		
	47	EP	526 511	B1		05-28-1997		
	48	EP	508 785	B1		03-15-2000		

Examiner Signature

Date Considered

10/31/03

*EXAMINER: Initially reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3244115 v1
PA 3243895 v22

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 15

Complete if Known

Application Number 09/724,940
Filing Date November 28, 2000
First Named Inventor Schenk, Dale B.
Group Art Unit 4774 Kaff
Examiner Name Unassigned Nicholas
Attorney Docket Number 15270J-004751US

49	EP	451 700	A1	10-18-1991	
50	EP	440 819	B1	01-24-1998	
51	EP	359 783	B1	11-29-1995	
52	EP	276 723	B1	12-08-1993	Yes
187	EP	783 104	A1	07-08-1987	
294	PCT	01/62801	A2	08-30-2001	
301	PCT	01/62284	A2	03-01-2000	
298	PCT	01/42308	A2	08-14-2001	
199	PCT	00/77178	A1	12-21-2000	
240	PCT	00/43039	A1	07-27-2000	
188	PCT	00/43049	A1	07-27-2000	
53	PCT	99/60024	A1	11-26-1999	
64	PCT	99/60021	A2	11-15-1999	
65	PCT	99/59504	A1	11-18-1999	
58	PCT	99/06066	A2	02-11-1999	
57	PCT	99/27948	A1	08-10-1999	
58	PCT	99/27944	A1	08-10-1999	
59	PCT	99/27911	A1	08-10-1999	
203	PCT	99/00150	A2	01-07-1999	
60	PCT	98/44955	A1	10-15-1998	
61	PCT	98/07850	A2	02-26-1999	
202	PCT	97/21728	A1	06-19-1997	
62	PCT	97/17613	A1	05-15-1997	
63	PCT	96/39178	A1	12-12-1996	
208	PCT	96/28471	A1	08-18-1996	
64	PCT	96/25435	A1	08-22-1996	
65	PCT	96/18900	A1	06-20-1996	
66	PCT	95/31898	A1	11-30-1995	
200	PCT	95/12815	A1	05-11-1995	
67	PCT	95/11994	A1	05-04-1995	
68	PCT	95/11311	A1	04-27-1995	
227	PCT	95/11008	A2	04-27-1995	
69	PCT	95/05653	A1	03-02-1995	
70	PCT	95/04151	A2	02-09-1995	
201	PCT	94/28412	A1	12-08-1994	
71	PCT	94/03815	A1	02-17-1994	
72	PCT	94/01772	A1	01-20-1994	
73	PCT	93/21950	A1	11-11-1993	
74	PCT	93/16724	A1	08-02-1993	
75	PCT	93/15760	A1	08-19-1993	

Examiner
Signature

[Signature]

Date
Considered

10/31/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1

PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,940
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Group Art Unit	4774 1647
				Examiner Name	Unassigned NICHOLS
Sheet	4	of	15	Attorney Docket Number	15270J-004751US

76	PCT	93/14200	A1	07-22-1993
205	PCT	93/04194	A1	03-04-1993
77	PCT	93/02189	A1	02-04-1993
78	PCT	92/13089	A1	08-08-1992
79	PCT	92/08708	A1	04-30-1992
80	PCT	92/08187	A1	04-18-1992
81	PCT	91/19810	A1	12-28-1991
82	PCT	91/18819	A1	11-14-1991
83	PCT	91/12816	A1	09-05-1991
84	PCT	91/08760	A1	08-27-1991
85	PCT	90/12871	A1	11-01-1990
86	PCT	90/12870	A1	11-01-1990
87	PCT	89/01343	A1	02-23-1989
88	PCT	89/08242	A1	07-13-1989
89	PCT	89/06889	A1	07-27-1989
90	PCT	89/03687	A1	05-05-1989
91	PCT	88/10120	A1	12-29-1988
92	GB	2 220 211	A	01-04-1990
93	GB	2 335 192	A	09-15-1990

Examiner Signature	<i>G. Nichols</i>	Date Considered	10/31/03
--------------------	-------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1

PA 3243895 v22

Please type a plus sign (+) inside this box → +

PTO/SB/06B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/724,940</td> </tr> <tr> <td>Filing Date</td> <td>November 28, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Schenk, Dale B.</td> </tr> <tr> <td>Group Art Unit</td> <td>4774-1647</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned- NICHOLS</td> </tr> <tr> <td>Attorney Docket Number</td> <td>15270J-004751US</td> </tr> </table>		Application Number	09/724,940	Filing Date	November 28, 2000	First Named Inventor	Schenk, Dale B.	Group Art Unit	4774-1647	Examiner Name	Unassigned- NICHOLS	Attorney Docket Number	15270J-004751US
Application Number	09/724,940														
Filing Date	November 28, 2000														
First Named Inventor	Schenk, Dale B.														
Group Art Unit	4774-1647														
Examiner Name	Unassigned- NICHOLS														
Attorney Docket Number	15270J-004751US														
Sheet	5	of	15												

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<div style="font-size: 2em; margin-bottom: 10px;">C</div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div> <div style="font-size: 2em;"> </div>	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," <i>Neurology</i> , 45:1441-1445 (1995).	<input type="checkbox"/>
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95).	<input type="checkbox"/>
	178	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8):916-919 (2000).	<input type="checkbox"/>
	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J. Mol. Biol.</i> , 225(4): 1075-1093 (1992).	<input type="checkbox"/>
	98	BAUER et al., "Interleukin-6 and α 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991).	<input type="checkbox"/>
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:58 PM ET.	<input type="checkbox"/>
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <i>Eur. J. Immunol.</i> , 29:345-354 (1999).	<input type="checkbox"/>
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <i>Soc. for Neuroscience Abstracts</i> 18:764 (1992).	<input type="checkbox"/>
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999).	<input type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990).	<input type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <i>Neuron</i> , 19: 939-945 (1997).	<input type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <i>Curr. Opin. Genet. Develop.</i> , 3: 102-109 (1993).	<input type="checkbox"/>
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg. Psychiatry</i> , 58:112-115 (1993).	<input type="checkbox"/>
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <i>Clin. Neuropharm.</i> , 15:414A-414B (1992).	<input type="checkbox"/>
	284	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, <i>Immunized in Vaccines (Mercury in Plasma-Derived Products)</i> , web site contents found at: http://www.fda.gov/cber/vaccine/thimerosal.htm , last updated May 16, 2002.	<input type="checkbox"/>

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1
PA 3147648 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	4771-1647
		Examiner Name	Unassigned- NICHOLS
Sheet 6 of 15	Attorney Docket Number	15270J-004751US	

102	CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <i>Soc. Neurosci. Abstracts</i> , 19:513.7 (1993).	<input type="checkbox"/>
266	CHAPMAN, PAUL F., "Model behavior," <i>Nature</i> , 408:915-918 (2000).	
292	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologics," Chemical Abstract database. (Publication date unknown.)	
213	CHEN et al., "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <i>Neuroscience Letters</i> 125:223-226 (1991).	
302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <i>J. Biol. Chem.</i> , 274(45):32301-32308 (1999).	
291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <i>Pharm. Res.</i> , 17:266-274 (2000).	
280	CORDELL, B., " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <i>Ann. Rev. Pharmacol. Toxicol.</i> , 34:89-89 (1994).	
287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <i>Scand. J. Immunol.</i> , 38:177-182 (1993).	
283	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <i>Life Sci.</i> , 63:2121-2131 (1998).	
214	DEMATTOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 10,1073/pnas.151261398 (2001).	
289	Dialog/Derwent, Abstract of WPI Abs. No. 1997-054456/199706, Stable vaccine compns. - comprises a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water-sol. organic solvent and saline or water, Derwent Ele. 264-Derwent WPI database. (Publication date unknown.)	
103	DUFF et al., "Mouse model made," <i>Nature</i> , 373: 476-477 (1995).	
288	DUMERY et al., " β -Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <i>Pathol. Biol.</i> , 49:72-85 (2001).	
225	Elian, "Elian and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).	
226	Elian, "Elian and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	
104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <i>J. Neurol. Sciences</i> , 59:341-347 (1983).	
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <i>Trends in Pharm. Sci.</i> , 22:2-3 (2001).	

CONS. (DETERED); DO NOT PRINT.

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1

PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	477-1647
		Examiner Name	Unassigned NICHOLS
Sheet 7 of 15	Attorney Docket Number	15270J-004751US	

105	FELSENSTEIN et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <i>Neuroscience Letters</i> , 152:185-189 (1993).	
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <i>Neurobiology of Aging</i> , 17(5):809-815 (1996).	
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <i>PNAS</i> , 88:1779-1782 (1991).	
108	FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <i>Neurology</i> , 45:1561-1569 (1995).	
248	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <i>Vaccine</i> , 19:2615-2619 (2001).	
247	FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <i>PNAS USA</i> , 97:11455-11459 (2000).	
248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>J. of Neuroimmunology</i> , 88:85-90 (1999).	
245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuroimmunology</i> , 85:136-142 (1999).	
244	FRENKEL, et al., "Modulation of Alzheimer's β -amyloid neurotoxicity by site-directed single chain antibody," <i>J. of Neuroimmunology</i> , 108:23-31 (2000).	
210	FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <i>Mol. Neurology</i> , 9:107-113 (1994).	
249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," In <i>Cerebrovascular Pathology in Alzheimer's Disease</i> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <i>Nature</i> , 373(6514): 523-527 (1995).	
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β 1-42," <i>Annals of the New York Academy of Science</i> 920:274-84 (2000).	
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <i>TIPS</i> , 13:108-113 (1992).	
261	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <i>Biochem. Biophys. Res. Comm.</i> , 173:1292-1298 (1990).	
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <i>J. Exp. Med.</i> , 177:1181-1186 (1993).	
252	GEDDES, "N-terminus truncated β -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <i>Neurobiology of Aging</i> , 20:75-78 (1999).	
253	GIULIAN, et al., "The HHQK Domain of β -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>Journal of Biological Chem.</i> , 273:28719-28726 (1998).	

Examiner Signature	<i>G. Nichols</i>	Date Considered	10/31/03
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1

PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1774-1647
		Examiner Name	Unassigned NICHOLS
Sheet 8 of 15	Attorney Docket Number	15270J-004751US	

112	GLENN et al., "Skin immunization made possible by cholera toxin," <i>Nature</i> , 391: 851 (1998).	—
114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <i>Biochemical and Biophysical Research Communications</i> , 122(3): 1131-1135 (1984).	—
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <i>Biochemical and Biophysical Research Communications</i> , 120(3): 885-890 (1984).	—
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <i>Nature</i> , 349:704-708 (1991).	—
303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <i>Immunology</i> , 93:149-153 (1998).	—
237	GORTNER, <i>Outlines of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).	—
118	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <i>PNAS USA</i> , 93:427-432 (1996).	—
190	GRAVINA et al., "Amyloid β Protein ($A\beta$) in Alzheimer's Disease," <i>J. Biol. Chem.</i> , 270(13):7013-7018 (1995).	—
254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?", <i>TINS</i> , 23:114 (2000).	—
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <i>Vaccine</i> , 15(12/13): 1341-1343 (1997).	—
241	HAASS et al., "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-5 (1992).	—
118	HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <i>Brain Research</i> , 601:86-94 (1993).	—
182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <i>Int. J. Exp. Clin. Invest.</i> , 3:130-133 (1996).	—
119	HANES et al., "New advances in microsphere-based single-dose vaccines," <i>Advanced Drug Delivery Reviews</i> , 28: 97-118 (1997).	—
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <i>TINS</i> , 20(4): 164-159 (1997).	—
121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <i>Annals of Med.</i> , 28:255-258 (1998).	—
255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <i>Biochem. Biophys. Res. Comm.</i> , 211:1015-1022 (1995).	—

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3244115 v1
PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1774-1147
		Examiner Name	Unassigned NICHOLS
		Attorney Docket Number	15270J-004751US
Sheet	9	of	15

183	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β /A4-protein," <i>Biochimica Biophysica Acta</i> , 1158:120-128 (1993).
229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", <i>Immunology</i> , Vol. 78: 643-649 (1993).
177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <i>Science</i> , 289:375 (2000).
236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991).
122	HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 274: 99-102 (1996).
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <i>J. Neuroimmunology</i> , 52:147-152 (1994).
174	Human Immunology & Cancer Program brochure from The University of Tennessee Medical Center Graduate School of Medicine, Knoxville, Tennessee (publication date unknown)
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <i>N. E. J. Medicine</i> , 333(19):1283-1284 (1995).
256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <i>Lab. Invest.</i> , 57:448-449 (1987).
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <i>J. Neuroimmunology</i> , 24:173-182 (1989).
192	IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <i>Neuron</i> , 13:45-53 (1994).
128	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <i>Immun. Rev.</i> , 62: 185-218 (1982).
257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <i>Brain Research Protocols</i> , 2:23-30 (1997).
216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <i>Am. J. of Pathology</i> 136:373-384 (1991).
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <i>Res. Immunology</i> , 143:637-641 (1992).
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <i>Biotechnol. Appl. Biochem.</i> , 23:227-230 (1996).
126	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <i>Nature</i> , 354:476-478 (1991).
258	KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <i>Neuroscience Letters</i> , 193:105-108 (1995).

CONSIDERED; DO NOT PRINT.

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1
PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1771 (047)
		Examiner Name	Unassigned NICHOLS
Sheet 10 of 15	Attorney Docket Number	15270J-004751US	

195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the A4 Peptide," <i>Annals of NY Acad. Sci.</i> , 777:344-355 (1996).	
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <i>Neurodegeneration</i> , 2:111-121 (1993).	
130	LANGER, "New Methods of Drug Delivery," <i>Science</i> , 249: 1527-1532 (1990).	
131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <i>Behavioural Brain Res.</i> , 57:207-213 (1993).	
259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <i>Curr. Ops. in Chemical Biology</i> , 1:260-267 (1997).	
132	LEMERE et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden in Pd-Ap β Transgenic Mice," <i>Society for Neuroscience Abstracts</i> , vol. 25, part 1, Abstract 519.6, 28th Annual Meeting, (October 23-28, 1999).	
260	LEMERE, et al., "Nasal A β treatment induces anti-A β antibody production and decreases cerebral amyloid burden in PD-APP mice," <i>Annals of the NY Acad. Sci.</i> , 920:328-331 (2000).	
184	LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <i>Biochem. Mol. Biol. Int.</i> , 43(3):601-611 (1997).	
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <i>J. Immunol.</i> , 159: 1383-1392 (1997).	
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <i>Acta. Neurol. Scand.</i> , 64:441-444 (1981).	
218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <i>The J. of Nuclear Med.</i> , 33:2184-2189 (1992).	
261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <i>Brain Research</i> , 667:138-142 (1994).	
263	MANN, et al., "Amyloid β protein (A β) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A β ₄₂ ," <i>Annals of Neurology</i> , 40:149-156 (1996).	
262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <i>Neuroscience Letters</i> , 196:105-108 (1995).	
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <i>Proc. Natl. Acad. Sci. USA</i> , 82:4245-4249 (1985).	
135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <i>J. Micro. Encap.</i> , 14(2): 197-210 (1997).	
264	McGeer, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <i>J. of Neuroscience Res.</i> , 31:428-442 (1992).	

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3244115 v1

PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1771
		Examiner Name	Unassigned
		Attorney Docket Number	15270J-004751US
Sheet	11	of	15

236	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <i>Virology</i> , 243:158-168 (1998).	
136	MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <i>Nature</i> , 374:647-650 (1995).	
265	Mena, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <i>Acta Neuropathol.</i> , 88:50-56 (1995).	
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <i>J. Exp. Med.</i> , 174:791-798 (1991).	
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <i>J. Biol. Chem.</i> , 267(24):17082-17088 (1992).	
233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <i>Neurology</i> , 39:1159-65 (1989).	
181	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <i>Am. J. Pathology</i> , 144(5):1082-1088 (1994).	
250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <i>Exp. Anim.</i> , 43:711-718 (1995).	
288	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (A β) subtypes (A β 40 and A β 42/43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <i>Neuroscience Letters</i> , 201:151-154 (1995).	
281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <i>J. of Med. Primatology</i> , 27:244-252 (1998).	
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <i>Am. J. Epidemiol.</i> , 145(11): 959-969 (June 1, 1997).	
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	
235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-486 (1965).	
280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <i>Biochem. Biophys. Res. Comm.</i> , 148:307-313 (1987).	
140	PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <i>Neuron</i> , 17:553-565 (September 1998).	
141	PAUL et al., "Transdermal Immunization with large proteins by means of ultradeformable drug carriers," <i>Eur. J. Immunol.</i> , 25: 3521-3524 (1995).	
232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <i>Laboratory Animal Science</i> , 48(1):8-14 (1998).	

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1
PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1774-1648
		Examiner Name	Unassigned DUCHES
Sheet 12 of 15	Attorney Docket Number	15270J-004751US	

269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 48:709-710 (1996).	
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).	
143	QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:238-241 (1991).	
145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	
144	RASO, V.A., Grant application # 1 R43 AG1 6740-01, "Immunotherapy of Alzheimer's Disease" (publication date unknown).	
304	RASO, V.A., Grant application # 1 R43 AG1 6748-01 (non-rejected version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).	
146	ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:188-202 (1993).	
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1978).	
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolyse in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	
278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:308-320 (1981).	
277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1987).	
148	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1998).	
178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	
270	SCHENK, et al., " β -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000).	
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	

CONSIDERED; DO NOT PRINT.

Examiner Signature	<i>G. Nichols</i>	Date Considered	10/31/03
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244115 v1
PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	7771-1647
		Examiner Name	Unassigned NICHOLS
Sheet 13 of 15	Attorney Docket Number	15270J-004751US	

151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends In Neurosciences</u> , 16(10): 403-409 (1993).	1
140	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	1
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	1
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	1
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	1
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:467-488 (1991).	1
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	1
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	1
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	1
185	SOLOMON and GOLDSTEIN, "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1998).	1
158	SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).	1
159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS USA</u> , 94:4109-4112 (1997).	1
180	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS USA</u> , 93:452-455 (1996).	1
101	SOLOMON, A., "Pro-Fx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).	1
102	SOLOMON, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel (publication date unknown).	1
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1998).	1
271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1999).	1

CONSIDERED, DO NOT PRINT.

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3244115 v1
PA 3243895 v22

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1771 1644
		Examiner Name	Unassigned NICHOLS
Sheet 14 of 15	Attorney Docket Number	15270J-004751US	

163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria", <i>N. Engl. J. Med.</i> , 336(2): 88-91 (1997).	—
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>PNAS</i> , 84: 13287-13292 (1987).	—
272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on <i>in vitro</i> properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <i>Int. J. Peptide Protein Res.</i> , 47:280-296 (1996).	—
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <i>European J. Pharmacology</i> , 352:135-142 (1998).	—
273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <i>Curr. Op. in Chem. Biology</i> , 4:377-382 (2000).	—
276	TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <i>Journal of Biological Chemistry</i> , 271:8545-8548 (1998).	—
168	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37, (1994).	—
167	VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neuroscience Letters</i> , 172:122-124 (1994).	—
168	VERBEEK et al., "Accumulation of Interleukin Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Jour. Pathology</i> , 144(1):104-118 (1994).	—
169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurology</i> , 53(4):377-383 (1994).	—
274	WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <i>Annals of Neurology</i> , 48:567-579 (2000).	—
171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994).	—
172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <i>Curr. Opin. Neurobiol.</i> , 7: 695-700 (1997).	—
180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <i>J. Food Drug Analysis</i> , 6(2):465-478 (1998).	—
170	WENGENACK et al., "Targeting Alzheimer amyloid plaques <i>in vivo</i> ," <i>Nature Biotech.</i> , 18:868-872 (2000).	—
225	Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 98. (Publication date unknown)	—
219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <i>PNAS USA</i> , 82:8728-8732 (1985).	—

CONSIDERED; DO NOT PRINT.

Examiner Signature	<i>G. Nichols</i>	Date Considered	10/31/03
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3244115 v1
PA 3243895 v22

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	4771 (CHP)
		Examiner Name	Unassigned - D/CHOCS
Sheet 15 of 15	Attorney Docket Number	15270J-004751US	

173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS USA</i> , 94: 1550-1555 (1997).	
276	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <i>J. Clin. Invest.</i> , 100:1804-1812 (1997).	
292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques, <i>Acta Neuropathol.</i> , 96:217-222 (1998).	
290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," <i>Nature Medicine</i> , 7:18-19 (2001).	

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3244115 v1

PA 3243895 v22



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1771 K47
Examiner Name	Not yet assigned NICHOLS
Attorney Docket Number	15270J-004751US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear ³
CW	243	US 60/168,594			

FOREIGN PATENT DOCUMENTS

Examiner Initials ⁴	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear ³	T ⁵
		Country Code ⁶	Number ⁴	Kind Code ⁷ (if known)				
CW	243	WO	01/39796	A2	08-07-2001			

Examiner Signature		Date Considered	10/31/03
-----------------------	--	--------------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3228047 v1

CONSIDERED; DO NOT PRINT.



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

































(use as many sheets as necessary)

Sheet 1 of 7

Complete If Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

U.S. PATENT DOCUMENTS

CITED PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	360	2003/0073655 A1	04-17-2003	Chain	
	370	2003/0068325 A1	04-10-2003	Wang	
	378	2002/0197258 A1	12-26-2003	Ghanbari et al.	
	366	2002/0187157 A1	12-12-2002	Jensen et al.	
	377	2002/0168377 A1	11-14-2002	Schaetzi	
	340	2002/0162129 A1	10-31-2002	Lannfelt	
	395	2002/0160394 A1	10-31-2002	Wu	
	326	2002/0136718 A1	09-26-2002	Raso	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Geffer et al.	
	325	2001/0102281 A1	08-01-2002	Raso	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	306	6,417,178 B1	07-09-2002	Klunk et al.	
	376	2002/0086847 A1	07-04-2002	Chain	
	405	6,399,314 B1	06-04-2002	Krishnamurthy	
	342	2002/0009445 A1	01-24-2002	Du et al.	
	381	2001/0021769 A1	09-13-2001	Prusiner	
	401	6,284,533 B1	09-04-2001	Thomas	
	345	2002/0077288 A1	06-21-2001	Frangione	
	346	5,935,927	08-10-1999	Vitek et al.	
	382	5,846,533	12-08-1998	Prusiner	
	321	5,837,672	11-17-1998	Schenk et al.	
	353	5,824,322	10-20-1998	Balasubramanian	
	357	5,778,468 B1	07-07-1998	Hauser et al.	
	380	5,750,361	05-12-1998	Prusiner et al.	
	373	5,721,130	02-24-1998	Seubert et al.	
	356	5,622,701	04-22-1997	Berg	
	320	5,593,846	01-14-1997	Schenk et al.	
	358	5,583,112 B2	12-10-1996	Kensil et al.	
	403	5,464,823	11-07-1995	Lehrer et al.	
	402	4,713,366	12-15-1987	Stevens	

Examiner
Signature

g. nichols

Date
Considered

10/31/03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60057393 v1

OCT 09 2003

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

7

Complete if known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
g	305	00/724,942	11-28-2000	Ghalifour et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
g	343	EP	1 172 378	A1	01-16-2002			
	351	WO	02/34878	A2	05-02-2002			
	352	WO	02/34777	A1	05-02-2002			
	341	WO	02/03911	A2	04-07-2001			
	344	WO	01/90182	A2	11-29-2001			
	348	WO	01/77167	A2	10-18-2001			
	322	WO	00/72880	A2, A3	12-07-2000			
	323	WO	00/72876	A2, A3	12-07-2000			
	324	WO	00/72870	A1	12-07-2000			
g	331	WO	99/06545	A2	11-02-1999			
g	383	WO	97/10505	A1	03-20-1997			

Examiner
Signature

g Nichols

Date
Considered

10/31/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60057393 v1

CONSIDERED TO NOT PRINT.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	09/724,940		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 28, 2000		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1647		
		Examiner Name	Christopher J. Nichols		
Sheet	3	of	7	Attorney Docket Number	15270J-004751US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	391	AGUZZI et al., "Prion research: the next frontiers," <u>Nature</u> , 389:795-798 (1997).	—
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," <u>Neurobiology of Aging</u> , 21:383-421 (2000).	—
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid β -Protein (A β) Deposits With Numerous A β -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <u>Glia</u> , 25:324-331 (1999).	—
	404	BENJAMINI and LESKOWITZ, from <u>IMMUNOLOGY A Short Course</u> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	—
	327	CAMERON, "Recent Advances in Transgenic Technology," <u>Molecular Biotechnology</u> , 7:253-265 (1997).	—
	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	—
	332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V \rightarrow F transgenic mice," <u>Progress in Brain Research</u> , Van Leeuwen et al. Eds, 117:327-337 (1998).	—
	307	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-9 (2000).	—
	333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000)	—
	390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," <u>Biochem. J.</u> , 320:53-570 (1996).	—
	363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?" <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).	—
	318	DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <u>Neurology</u> , 57(5):801-5 (2001).	—

Examiner Signature		Date Considered	10/31/03
-----------------------	--	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60057393 v1

OCT 09 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

7

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing," <i>Alzheimer's and Parkinson's Diseases</i> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).	
386	FRATUTSCHY et al., "Effects of injected Alzheimer β -amyloid cores in rat brain," <i>PNAS</i> , 88:8362-8366 (1991).	
364	FURLAN et al., "Vaccination with amyloid- β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <i>Brain</i> , 126:285-291 (2003).	
388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <i>Ann. Rev. Med.</i> , 46:57-65 (1995).	
397	GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants," <i>PNAS</i> , 96:3108-3113 (1999).	
374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <i>Alzheimer Disease and Associated Disorders</i> , 9(1):47-51, Raven Press, Ltd., New York (1995).	
308	JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <i>Nature</i> , 408(6815):979-82 (2000).	
334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991).	
371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β -Amyloid Peptide (1-43) in Transfected 293 Cells," <i>Biochemical and Biophysical Research Communications</i> , 220:710-718 (1996).	
347	JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <i>Infection and Immunity</i> , May:497-502 (1981).	
389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <i>J. Neurol.</i> , 249:1567-1582 (2002).	
335	MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <i>PNAS</i> , 98(21):12245-12250 (2001).	
309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <i>Physiol Rev.</i> 77(4):1081-132 (1997).	

Examiner
SignatureDate
Considered

10/31/03

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60057393 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	09/724,940		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 28, 2000		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1647		
		Examiner Name	Christopher J. Nichols		
Sheet	5	of	7	Attorney Docket Number	15270J-004751US

310	MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000).	
367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid β -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001).	
311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-5 (2000).	
359	MUNCH et al., "Potential neurotoxic inflammatory response to A β vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087.	
355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	
354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, <u>medpharm</u> Scientific Publishers, Stuttgart, Germany.	
350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	
329	NIEMANN, "Transgenic farm animals get off the ground," <u>Transgenic Research</u> 7:73-75 (1998).	
398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 7:703-707 (2001).	
406	PAN et al., "Antibodies to β -Amyloid Decrease the Blood-to-Brain Transfer of β -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):609-615 (2002).	
336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).	
394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993).	
312	SCHENK, et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001).	
313	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998).	

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60057393 v1



PTO/SB/04B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

7

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

	330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000).	
	396	SIGURDSSON et al., "Anti-prior antibodies for prophylaxis following prion exposure in mice," <u>Neuroscience Letters</u> , 336:185-187 (2003).	
	384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002).	
	314	SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000).	
	400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?", <u>Neurobiology of Aging</u> , 23:1001-1008 (2002).	
	315	SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann NY Acad Sci.</u> , 920:206-8 (2000).	
	368	SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992).	
	337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech.</u> , 18(1):34-39 (2000).	
	319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <u>Nat Rev Neurosci.</u> 2(8):595-8 (2001).	
	316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. <u>Nat Med.</u> 4(7):822-6 (1998).	
	369	SPOONER et al., "The generation and characterization of potentially therapeutic A β antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002).	
	338	STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <u>The Journal of Neuroscience</u> , 22(17):7380-7388 (September 1, 2002).	
	361	SU et al., "Intravascular infusions of soluble β -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999).	
	392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003).	

Examiner
Signature

Date

Considered

10/31/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60057393 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	15270J-004751US
Sheet	7	of	7

<input checked="" type="checkbox"/>	399	TAN et al., "Amyloidosis," <u>Histopathology</u> , 25:403-414 (1994).	<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4299-4303 (1995).	<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	375	TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopathy using end-specific antibodies for A β 40 and A β 42: Immunohistochemical evidence for amyloid β protein," <u>Neuroscience Letters</u> , 2002:77-80 (1995).	<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPsw/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <u>DNA Cell Biol.</u> (11):713-21 (2001).	<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	387	WELDON et al., "Neurotoxicity of A β Peptide: Confocal Imaging of Cellular Changes Induced by - Amyloid in Rat CNS <i>In Vivo</i> ," <u>Society for Neuroscience Abstracts</u> , 22(Part 1) (1996).	<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	385	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):574-587 (2002).	<input checked="" type="checkbox"/>

Examiner Signature		Date Considered	10/31/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60057393 v1



→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	442	6,713,450 B2	03-30-2004	Frangione et al.	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	431	2003/0165496 A1	09-04-2003	Basi et al.	
	432	6,562,341 B2	05-13-2003	Prusiner et al.	
	440	2003/0068316 A1	04-10-2003	Klein et al.	
	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
	511	US-6,331,440	12-18-2001	Nordstedt, et al.	
	516	US-6,261,569	07-17-2001	Cornis et al.	
	452	6,218,506 B1	04-17-2001	Krafft et al.	
	510	US-6,022,859	02-08-2000	Kiessling, et al.	
	512	US-5,891,991	04-06-1999	Wasco et al.	
	445	5,854,215	12-29-1998	Findeis et al.	
	446	5,817,626	10-06-1998	Findeis et al.	
	451	5,766,846	06-16-1998	Schlossmacher et al.	
	515	US-5,652,334	07-29-1997	Roberts	
	513	US-5,514,548	05-07-1996	Krebber et al.	
	514	US-5,470,951	11-28-1995	Roberts	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	433	WO	03/020212	A2	03-13-2003			
	441	WO	03/104437	A2	12-18-2003			
	443	WO	03/074081	A1	09-12-2003			
	447	WO	03/051374	A2	06-26-2003			
	450	WO	01/18169	A3	03-15-2001			
	454	WO	98/33815	A1	08-06-1998			
	455	WO	01/10900	A2	02-15-2001			
	456	WO	02/021141	A2	03-14-2002			
	457	WO	02/046237	A1	06-13-2002			
	458	WO	02/060481	A1	08-08-2002			

Examiner Signature	<i>Linco</i>	Date Considered	8/30/04
-----------------------	--------------	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60277165 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

517	WO	94/05311	A1	03-17-1994			
518	WO	95/23166	A1	08-31-1995			
519	WO	00/26238	A2	05-11-2000			
520	WO	98/22120	A1	05-28-1998			
521	WO	98/05350	A1	02-12-1998			
522	WO	00/20027	A2	04-13-2000			
523	EP	752 886	B1	01-28-1998			
524	WO	95/05393	A2	02-23-1995			
525	WO	98/02462	A1	01-22-1998			
526	WO	99/06587	A2	02-11-1999			
527	WO	97/32017	A1	09-04-1997			
528	WO	97/08320	A1	03-06-1997			
529	WO	00/68263	A2	11-16-2000			
530	WO	98/08868	A1	03-05-1998			
531	WO	95/08999	A1	04-06-1995			
532	WO	96/37621	A2	11-28-1996			
533	AU	707083		07-01-1999			


Examiner Signature		Date Considered	8/30/04
-----------------------	--	--------------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

60277165 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	448	ANDREW et al., <i>Current Protocols in Immunology</i> , 2.7.1-2.9.8 (1997).	—
	484	ARENDIASH GW et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <i>DNA and Cell Biology</i> , 20(11):737-744 (2001)	—
	485	BACSKAI BJ et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <i>Nature Medicine</i> , 7(3):369-372 (2001)	—
	504	BALBACH J et al., "Amyloid fibril formation by A β ₁₆₋₂₂ , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR" <i>Biochemistry</i> , vol. 39, pp. 13748-59 (2000)	—
	540	BENKIRANE, et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>The Journal of Biological Chemistry</i> , 268(23):26279-26285 (1993).	—
	461	BURDICK D et al., "Assembly and aggregation properties of synthetic Alzheimer's A β amyloid peptide antigens," <i>J Biol Chem</i> , 267:546-55 (1992)	—
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <i>J. Biol. Chem.</i> , 276(24):21562-70 (2001).	—
	509	CIRRITO et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <i>J. Clin. Invest.</i> , 112:321-323 (2003)	—
	462	CO et al. "Chimeric and humanized antibodies with specificity for the CD33 antigen," <i>J Immunol</i> , 148:1149-1154 (1992)	—
	541	CRIBBS et al., "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All -L-Beta-Amyloids," <i>J. Biol. Chem.</i> , 272:7431-7436 (1997).	—
	412	DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out-Mice," <i>J. Neuroscience</i> , 23(24):8532-8538 (2003).	—
✓	469	DEMATTO RB et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease ³ ," <i>Proc Natl Acad Sci USA</i> 98(15):8850-8855 (17 July 2001)	—
	493	DEMATTO RB et al., "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease," <i>J Neurochem</i> , 81:229-236, (2002)	—

Examiner
Signature

Date
Considered

8/30/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

CSW	486	DICKEY CA et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001)	
	436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only	
	407	ECK et al., <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , Chapter 5, pages 77-101 (1996)	
	475	EL-AGNAF OM et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur J Biochem</u> , 256(3):560-569 (1998)	
	501	ESLER W et al., "Point substitution in the central hydrophobic cluster of a human β -amyloid congener disrupts peptide folding and abolishes plaque competence" <u>Biochemistry</u> , vol. 35, pp. 13914-21 (1996)	
	539	FINDEIS, et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <u>Biochemistry</u> , 38:6791-6800 (1999).	
	464	FLOOD JF et al., "An amyloid β -Protein fragment, A β [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures," <u>Brain Res</u> , 663(2):271-276 (1994)	
	538	FLOOD, et al., "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein," <u>PNAS</u> , 91:380-384 (1994).	
	463	GHISO J et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <u>Biochem J</u> , 282 (Pt 2):517-522 (1992)	
	470	GIULIAN D et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <u>J Neurosci</u> , 16 (19):6021-6037 (1996)	
	503	GOREVIC P et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , vol. 147, no. 2 (1987)	
	487	HAASS C et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?" <u>Nature Neuroscience</u> , 4(9):859-860 (2001)	
	476	HE X-Y et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J Immunol</u> , 160:1029-1035 (1998)	
CSW	473	HILBICH C et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease" <u>J. Mol. Biol.</u> , 218:149-163 (1991)	

Examiner
SignatureDate
Considered

8/30/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

471	HILBICH C et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <u>J. Mol. Biol.</u> , 228:460-473 (1992)	
534	HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).	
413	HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	
434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).	
488	KLEIN WL et al., "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?" <u>Trends in Neurosciences</u> , 24(4):219-224 (2001)	
494	KOTILINEK LA et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J Neurosci</u> , 22(15):6331-6335 (2002)	
465	KOUDINOV A et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem & Biophys Res Comm</u> , 205:1164-1171 (1994)	
478	KUO YM et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem Biophys Res Commun</u> , 257(3):787- 791 (1999)	
477	LAMBERT MP et al., "Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins," <u>Proc Natl Acad Sci</u> , 95:6448-6453 (1998)	
489	LAMBERT MP et al., "Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies," <u>J Neurochem</u> , 79:595-605 (2001)	
490	LEE VM-Y et al., "A β immunization: Moving A β peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001)	
459	LEVITT M. "Molecular dynamics of native protein," <u>J. Mol Biol</u> , 168:595-620 (1983)	
481	LEVY A et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?" <u>American Neurological Assoc</u> , 48:553-554 (2000)	
499	LUE L et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease", <u>Am. J. Pathol.</u> , 1999, 155: pp 853-62 (September 1999)	
502	MAGGIO J & MANTYH P "Brain Amyloid - A Physicochemical Perspective" <u>Brain Pathology</u> , vol. 6, 147-162 (1996)	

Examiner
Signature

[Signature]

Date
Considered

8/30/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60277165 v1



→

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/724,940
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	15270J-004751US
Sheet	6	of	8


408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).	
479	MCLEAN C et al., " Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer Neurological Assoc</u> , 46:860- 866 (1999)	
439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <u>Can. J. Neurol. Sci.</u> , 18(3 suppl.):424-427 (1991), abstract only	
482	NASLUND J et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <u>J Am Med Assoc</u> , 283:1571 (2000)	
409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995	
437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only	
491	PODUSLO JF et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol Dis</u> , 8(4):555-67 (2001)	
460	QUEEN C et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>Proc Natl Acad Sci USA</u> , 86:10029-10033 (1989)	
497	RAGUSI C et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies" <u>J. Neurochem.</u> , Vol. 70, No. 5, pp 2099-105 (1998)	
414	SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).	
466	SCHWARZMAN AL et al., "Transthyretin sequesters amyloid β protein and prevents amyloid formation," <u>Proc Natl Acad Sci</u> , 91:8368-8372, (1994)	
536	SELA et al, "Different roles of D-amino acids in immune phenomena," <u>FASEB J</u> , 11(6):449-456 (1999).	
505	SIMMONS L "Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro" <u>Molecular Pharmacology</u> , vol. 45, pp 373-9 (1994)	
438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only	

Examiner Signature		Date Considered	8/30/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7

of

8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

411	SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).
508	SOTO C et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation" <i>J. Biol. Chem.</i> , vol. 270, no. 7, pp 3063-67 (1995)
435	STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <i>FEBS Letters</i> , 264(1):43-47 (1990).
496	STRBAK V et al., "Passive Immunization and Hypothalamic Peptide Secretion", <i>Neuroendocrinology</i> , 1993; 58:210-217 (August 1993)
498	SUO et al., "Soluble Alzheimers β -amyloid constricts the cerebral vasculature in vivo" <i>Neuroscience Letters</i> 257, pp 77-80 (1998)
467	TABATON M et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <i>Biochem and Biophys Res Comm</i> , 200(3):1598-1603 (1994)
472	TELLER J et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <i>Nature Medicine</i> , 2(1):93-95 (1996)
500	TJEMBERG L et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation" <i>J. Biol. Chem.</i> , vol. 274, no. 18, pp 12619-25 (1999)
537	TJERNBERG, et al., "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <i>J. Biol Chem.</i> , 272(19):12601-12605 (1997).
492	TOWN T et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <i>Neurosci Lett</i> , 307:101-104 (2001)
535	VAN REGENMORTEL et al., "D-peptides as immunogens and diagnostic reagents," <i>Curr. Opin. Biotech.</i> 9(4):377-382 (1998).
410	VERMA et al., "Gene therapy - promises, problems and prospects," <i>Nature</i> , 389:239-242 (1997).
495	WANG H-W et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <i>Brain Research</i> , 924:133-140 (2002)
480	WANG J et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <i>Experimental Neurology</i> , 158:328-337 (1999)


Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,940
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	15270J-004751US
Sheet	8	of	8

474	WINTER G et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1996)	
468	WISNIEWSKI T et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol Aging</u> , 15(2):143-52 Review (1994)	
506	WOOD, A et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4" <u>Biochemistry</u> , vol. 34 pp: 724-30 (1995)	
507	XU S and GASKIN F "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease" <u>Mechanisms of Ageing and Development</u> , vol. 94, pp 213-22 (1997)	
430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	
483	ZLOKOVIC BV et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?" <u>Nature Medicine</u> , 6(7):718-719 (2000)	

Examiner Signature		Date Considered	9/30/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1